Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.
FAIL · Does not pass the screen
17.29 USD
At the last full screen 2025-12-31
Screened 2025-12-31 · the tape above runs as of 23:00 UTC · 20 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 17.29 against the desk's fair-value range, base estimate 20.00, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price17.29 USD
Fair value20.00
Ethical score70.0/100
Our investment reviews on this name
2026-08-22Read Markup17.29+0.0% to today ✓
2026-07-02Read Accumulation14.53+19.0% to today ✓
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Beta Bionics Inc holds its Markup at $17.29. The statistical read favours the sellers, held for 1 days.
As held on the ledger · 2025-12-31
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 1 days
Price at the screen
$17.29
Valuation
N/A trailing · -7.23 forward price to earnings
Values screen
FAIL· score 70.0
The Workings
Five Screens, Shown in Full
Does not pass. Revenue purity
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
2.22%
Below 33%
Interest-bearing debt is just 2.2% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
13.82%
Below 33%
Cash held in interest-bearing accounts and securities is 13.8% of assets, under the one-third limit.
Pass
Receivables
14.81%
Below 49%
Money owed to the company is 14.8% of assets, under the 49% limit.
Pass
Revenue purity
10.90%
Below 5%
10.9% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2025-12-31 screen. The gold marker is the market price at the same screen. A 15.7% margin of safety to the base estimate.
Third-party analyst targets: 10 covering, consensus Buy. The average target sits +16% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2025-12-31 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
BBNX trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-22Markup · changed$17.29+0.0%Entry 5
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (11 analysts) rates it none, with a mean price target of $19.
2026-07-22Accumulation$17.29+19.0%Entry 4
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 19.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (11 analysts) rates it none, with a mean price target of $19.
2026-07-18Accumulation$14.53+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (11 analysts) rates it none, with a mean price target of $19.
2026-07-03Accumulation$14.53+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Accumulation$14.53Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.